How to protect yourself from tick-borne encephalitis?

PATENT:

2795800

INVENTION:

Immunobiological agent for the prevention of diseases caused by tick-borne encephalitis virus based on a recombinant virus of the genus Flavivirus

INNVENTOR(S):

Kuznetsova Nadezhda Anatolyevna, Sinyavin Andrey Eduardovich, Usachev Evgeny Valeryevich, Pochtoviy Andrey Andreevich, Nikiforova Maria Andreevna, Shchetinin Alexey Mikhailovich, Shidlovskaya Elena Vladimirovna, Divisenko Elizaveta Vladimirovna, Vasilchenko Lyudmila Aleksandrovna, Zolotar Anastasia Nikolaevna, Butenko Alexander Mikhailovich, Larichev Viktor Filippovich, Zakharova Anastasia Andreevna, Remizov Timofey Andreevich, Rubalsky Oleg Vasilyevich, Tokarskaya Elizaveta Aleksandrovna, Tkachuk Artem Petrovich, Gushchin Vladimir Alekseevich, Logunov Denis Yurievich, Ginzburg Alexander Leonidovich

PATENTEE:

The National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation

PURPOSE:

For the prevention of tick-borne encephalitis

INNOVATION:

Tick–borne encephalitis virus (TBEV), propagated by ticks, is the main causative agent in humans of the tick-borne encephalitis. Infection with TBEV often has neurological manifestations - meningitis, encephalitis and meningoencephalitis. This leads to lifelong neurological complications and can lead to death. Every year thousands of people get sick after a tick bite, and for hundreds of them the disease has severe outcomes - disability or death.

The most effective way of specific prevention of tick-borne encephalitis is vaccination, which reduces the likelihood of the disease tenfold, prevents the development of severe complications. Employees of the N.F. Gamaleya National Research Center of Epidemiology and Microbiology have created an immunobiological agent for the prevention of diseases caused by TBEV based on a recombinant virus of the genus Flavivirus, obtained using methods of genetic engineering, reverse genetics and denovo gene synthesis. The agent is a vector virus of the genus Flavivirus, in which part of the proteins are replaced by proteins of another virus of the genus Flavivirus.

SCOPE OF
APPLICATION:

The invention relates to the field of biotechnology and medicine.

For more details please refer to the published patent.